MB-105 in Patients With CD5 Positive T-cell Lymphoma

Recruiting

Phase 2

MB-105MB-105 in Patients With CD5 Positive T-cell Lymphoma

Sponsor:

March Biosciences Inc

Code:

NCT06534060

Conditions

Lymphoma, T-Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Genetic: MB-105

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by March Biosciences Inc on 2025-05-08.